Skip to content

Exploring biomarkers for autism spectrum disorders

Exploring biomarkers for autism spectrum disorders

Status
Recruiting
Phases
Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400086877
Enrollment
Unknown
Registered
2024-07-15
Start date
2024-07-15
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

autism spectrum disorder

Interventions

Control group:None

Sponsors

Guangzhou Women and Children's Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
2 Years to 8 Years

Inclusion criteria

Inclusion criteria: 1. ASD group: (1) Initial diagnosis (2) Diagnosis age 2-8 years old (3) Patients meeting the DSM-V diagnostic criteria for autism spectrum disorder and scores of CARS= 30; (4) Evidence of a subject (or a legal representative) signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study and are willing to participate in it. 2. Control group: (1) Age 2-8 years old; (2) After clinical evaluation by the physician, there is no neurodevelopmental disorder, and the Autism Behavior Checklist (ABC) score is less than 30 points; (3) Children with normal intellectual development who require cerebrospinal fluid puncture for examination, such as spinal muscular atrophy, hydrocephalus, epilepsy, etc. (4) No direct relatives of ASD; (5) Evidence of a subject (or a legal representative) signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study and are willing to participate in it.

Exclusion criteria

Exclusion criteria: 1. ASD group (1) Individuals with schizophrenia in children and adolescents, selective mutism, specific sensory language disorders, hearing or visual impairments; (2) Individuals with diseases such as Rett syndrome and fragile X syndrome that may manifest as ASD; (3) Individuals with cerebral palsy, epilepsy, and severe organ diseases (such as hepatitis, encephalitis, congenital malformations, etc.). 2. Control group Individuals with cerebral palsy or severe organ diseases (such as hepatitis, encephalitis, congenital malformations, etc.).

Design outcomes

Primary

MeasureTime frame
Neurotransmitter;

Secondary

MeasureTime frame
Protein;

Countries

China

Contacts

Public ContactXingrong Song

Guangzhou Women and Children's Medical Center

sxjess@126.com+86 139 2241 6303

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026